Trials / Completed
CompletedNCT00004008
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- University of Glasgow · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian epithelial cancer that has not responded to previous chemotherapy.
Detailed description
OBJECTIVES: * Evaluate the antitumor activity and toxicity of bryostatin 1 in patients with platinum resistant ovarian epithelial cancer. * Determine the response rate in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive bryostatin 1 IV over 24 hours. Treatment repeats weekly for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or regressive disease may receive additional treatment. Patients are followed for at least 4 weeks after treatment, then every 3 months. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bryostatin 1 |
Timeline
- Start date
- 1999-07-01
- Completion
- 2003-05-01
- First posted
- 2003-05-08
- Last updated
- 2013-06-26
Locations
4 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00004008. Inclusion in this directory is not an endorsement.